<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809493</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0659</org_study_id>
    <nct_id>NCT04809493</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Effect of Isonatremic Dialysis Treatment in Chronic Kidney Disease Patients on Dialysis</brief_title>
  <acronym>DISON-IRC</acronym>
  <official_title>Evaluation of the Effect of Isonatremic (vs Conventional) Dialysis Treatment on the Control of Interdialytic Weight Gain in Chronic Kidney Disease Patients on Dialysis (Stage 5D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate, in a population of chronic kidney disease patients on&#xD;
      dialysis (Stage 5D), the effect of treatment with isonatremic dialysis (vs conventional&#xD;
      dialysis), during an observational period of 2 months each, on:&#xD;
&#xD;
        -  control of interdialytic weight gain&#xD;
&#xD;
        -  perdialytic tolerance in terms of adverse events occurring during all of the sessions of&#xD;
           the study&#xD;
&#xD;
        -  body composition and thirst measured monthly during the 4 months of follow-up.&#xD;
&#xD;
        -  tolerance to treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of interdialytic weight gain during treatment</measure>
    <time_frame>1, 2, 3 and 4 months after inclusion</time_frame>
    <description>change of interdialytic weight gain during treatment with isonatremic dialysis vs conventional dialysis during an observational period of 2 months each one.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perdialytic tolerance in terms of adverse events occurring</measure>
    <time_frame>1, 2, 3 and 4 months after inclusion</time_frame>
    <description>Perdialytic tolerance in terms of adverse events occurring during all sessions of the study with isonatremic dialysis vs conventional dialysis for an observational period of 2 months each one.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>1, 2, 3 and 4 months after inclusion</time_frame>
    <description>Body composition monthly during treatment with isonatremic dialysis vs conventional dialysis during an observational period of 2 months each one.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Tolerance</measure>
    <time_frame>1, 2, 3 and 4 months after inclusion</time_frame>
    <description>Rate of Tolerance during treatment with isonatremic dialysis vs conventional dialysis during an observational period of 2 months each one.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>patients will be receiving conventional dialysis</arm_group_label>
    <description>Patients will be receiving conventional dialysis treatment followed by isonatremic dialysis treatment during an observational period of 2 months for each treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional dialysis treatment</intervention_name>
    <description>Conventional dialysis treatment</description>
    <arm_group_label>patients will be receiving conventional dialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Isonatremic dialysis treatment</intervention_name>
    <description>Isonatremic dialysis treatment</description>
    <arm_group_label>patients will be receiving conventional dialysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients issued from dialysis units (hospital, clinic, non profit dialysis centers)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Chronic Kidney Disease patient on dialysis (stage 5D)&#xD;
&#xD;
          -  With plasma sodium concentration between 130 and 140 mmol/L&#xD;
&#xD;
          -  Anuric&#xD;
&#xD;
          -  Patient dialysed with dialysis machine allowing isonatremic dialysis treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient with plasma sodium concentration below 130 or above 140 mmol/&#xD;
&#xD;
          -  Pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <phone>+33(0)4 67 33 83 15</phone>
    <email>jp-cristol@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Paul Cristol, Prof</last_name>
      <phone>4 67 33 83 15</phone>
      <phone_ext>33</phone_ext>
      <email>jp-cristol@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Yves BOSC, MD</last_name>
      <phone>430 781 868</phone>
      <phone_ext>33</phone_ext>
      <email>j.bosc@aidersante.com</email>
    </contact_backup>
    <investigator>
      <last_name>Farid SAIDANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène LERAY-MORAGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile TURC-BARON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas BACHELET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franck LEROY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Sébastien SOUWEINE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hadia HEBIBI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease patient on dialysis (stage 5D)</keyword>
  <keyword>Extracorporeal purification</keyword>
  <keyword>Isonatremic dialysis</keyword>
  <keyword>Sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

